Journal
FUTURE MEDICINAL CHEMISTRY
Volume 2, Issue 12, Pages 1729-1733Publisher
FUTURE SCI LTD
DOI: 10.4155/FMC.10.243
Keywords
antipsychotic drugs; body weight; obesity; pharmacotherapy; psychological health; weight loss drugs
Categories
Ask authors/readers for more resources
The history of pharmacologic treatment of obesity is characterized by too much focus on efficacy and too little on safety, which has led to withdrawals of drugs from the market after serious adverse events. The development of new drug targets for the management of obesity will definitively need to address effects of the CNS and overall cardiovascular safety in the early stages in order to avoid the mistakes from the past. For instance, weight loss can increase the symptoms of depression and promote a state of psychobiological vulnerability favoring weight regain. Body-weight management should then seek a balance between the health benefits of weight loss and its potential risks, a 'zone' that is associated with an optimal psychobiological well-being.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available